NVAX
Novavax Inc.
Company Overview
| Mkt Cap | $1.21B | Price | $6.57 |
| Volume | 2.92M | Change | -1.79% |
| P/E Ratio | -6.5 | Open | $6.70 |
| Revenue | $682.2M | Prev Close | $6.69 |
| Net Income | $-187.5M | 52W Range | $5.01 - $11.55 |
| Div Yield | N/A | Target | $12.67 |
| Overall | 37 | Value | 40 |
| Quality | 47 | Technical | 25 |
No chart data available
About Novavax Inc.
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Latest News
Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX)
MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVAX | $6.57 | -1.8% | 2.92M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |